Clinical Trial Update: First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort [EARLY_Phase 1]

View source ↗

Summary

First-in-human SAD/MAD safety and pharmacokinetic study of an investigational therapy for Duchenne muscular dystrophy by Satellos Bioscience has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Investigational therapy (Satellos Bioscience, Inc.)

Snippet

Sponsor: Satellos Bioscience, Inc. | Conditions: Duchenne Muscular Dystrophy | EARLY_Phase 1 | Status: COMPLETED